Maravai outlines $33M-$35M 2026 adjusted EBITDA outlook while maintaining $205M-$215M revenue range (NASDAQ:MRVI)
Earnings Call Insights: Maravai LifeSciences (MRVI) Q2 2026 Management View "We are very pleased with our second quarter performance, which ...



-1024x683.jpg)









